Savinvest India Asia Fund

Quarterly Portfolio Statement |

September 30 2024

Fund Objective

The SavInvest India Asia Fund is an open-ended fund which aims to seek long-term growth of capital by investing in a diversified portfolio of equity securities of not less than 80% in issuers domiciled in India and other secondary Asian jurisdictions.

Fund Characteristics

Date of Inception:
October 03 2005
Minimum Investment:
USD 2,000.00
Minimum Addit. Investment:
USD 100.00
Investment Style:
Long-Term Growth
Asset Class Focus:
Equities

Benchmark: BSE 100, MSCI Asia Ex Japan


Top 10 Positions held by the SIAF

Security	% of Fund
IShares MSCI AC Asia Ex-Japan Index	7.5%
WisdomTree India Earnings Fund	6.5%
iShares MSCI India ETF	5.9%
IShares MSCI South Korea	5.8%
IShares MSCI Taiwan Index Fund	5.6%
Invesco India ETF	5.4%
Franklin FTSE India ETF	5.3%
IShares India 50 ETF	5.3%
China Equity Class A Fund	5.1%
Ishares MSCI India Small-Cap ETF	4.4%

Bourse

Yearly Performance


Managed by



Returns	Unit NAV TT\$	NAV Change (TT\$)	Total Return (%)	Annualized Return (%)
Year to Date	12.81	1.0	8.8%	
1 Month	12.72	0.1	0.7%	
3 Month	12.49	0.3	2.5%	
6 Month	11.71	1.1	9.4%	
1 Year	11.08	1.7	15.5%	
3 Year	13.09	(0.3)	0.1%	0.0%
5 Year	10.13	2.7	32.4%	5.8%
Inception	10.00	2.8	50.7%	2.2%

Fund Allocation

Geographic




Total Net Asset Value as at September 30, 2024

Funds Under Management as at September 30, 2024: US\$5.04 Million

The Net Asset Value of the Fund consists of only long positions.

The Summary of the Investment Portfolio may change due to ongoing portfolio transactions of the CIS and a quarterly update is available.

Asset Class



Methodology used to calculate Net Asset Value:

The Net Asset Value is calculated by dividing the total value of all Receivables, Cash and Securities in the Fund's portfolio minus any liabilities by the number of outstanding units.

"This document has been prepared by Bourse Securities Limited, ("Bourse"), for information purposes only. The production of this publication is not to in any way establish an offer or solicit for the subscription, purchase or sale of any of the securities stated herein to US persons or to contradict any laws of jurisdictions which would interpret our research to be an offer. Any trade in securities recommended herein is done subject to the face that Ha Bourse, its subsidiaries and/or affiliates have or may have specific or potential conflicts of interest in respect of the security or the issuer of the security, including those arising from [0] to trading or dealing in certain securities and acting as an investment advisor; (ii) holding of securities of the issuer as beneficial owner; (iii) having benefitted, benefitted, benefitted, benefitted protein protein fit from compensation arrangements; (iv) acting as underwriter in any distribution of securities of the issuer in the three years immediately preceding this document; or (v) having direct or indirect financial or other interest in the security or the issuer of the security. Investors are advised accordingly. Neither Bourse nor any of its subsidiaries, affiliates directors, officers, employees, representatives or agents, accepts any liability whatsoever for any direct, indirect or consequential losses arising from the use of this document or its contents or reliance on the information contained herein. Bourse does not guarantee the accuracy or completeness of the information in this document, which may have been obtained from or is based upon trades and statistical services or other third party sources. The information in this document is not intended to and no assurances are given with threspect therefor.

Telephone: Fax E-mail Web